Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Oncogenic K-RAS mutations drive approximately 25% of human lung cancers, primarily at codon 12.
• Current K-RAS inhibitors target specific mutations but often lead to acquired resistance.
• RUNX3, a critical cell fate regulator, is frequently inactivated in K-RAS-activated lung cancers.

Purpose of the Study:

• To investigate the therapeutic potential of RUNX3 restoration in K-RAS-activated lung cancer.
• To determine the mechanisms by which RUNX3 impacts tumor progression and recurrence.

Main Methods:

• Utilized a K-RAS-activated mouse lung cancer model.
• Conducted conditional restoration of Runx3 in established tumors.
• Analyzed tumor regression, recurrence, survival rates, and molecular pathways (Arf-p53).

Main Results:

• Conditional Runx3 restoration significantly regressed both adenomas and adenocarcinomas.
• Runx3 restoration suppressed cancer recurrence and markedly increased mouse survival.
• Tumor suppression was mediated by Arf-p53 pathway-induced apoptosis and p53-independent proliferation inhibition.

Conclusions:

• RUNX3 acts as a tumor suppressor in K-RAS-activated lung cancer.
• Restoration of RUNX3 demonstrates significant therapeutic potential for durable treatment of K-RAS-driven lung cancers.
• RUNX3 represents a viable therapeutic target for overcoming resistance to current K-RAS therapies.